EGFR and non-small cell lung carcinoma: ivonescimab has demonstrated promising antitumor activity and a manageable safety profile in patients with EGFR-mutant advanced NSCLC who had progressed on prior EGFR-TKIs therapy, as well as in those with advanced NSCLC refractory to platinum-based chemotherapy, PD-1/PD-L1 inhibitors, and antiangiogenic therapies (14, 19).